title: Drug-induced gynecomastia.
abstract: Gynecomastia is a relatively common physical finding in men. A wide variety of drugs have been implicated in its cause. Sufficient evidence in the literature suggests that calcium-channel blockers, cancer chemotherapeutic agents, and histamine2-receptor blockers may play a role in the disorder. Evidence for digitalis glycosides and neuroleptic agents is insufficient. Ketoconazole and spironolactone can also produce gynecomastia, and data for marijuana are contradictory. Large numbers of drugs have only case reports of temporal association with the disorder.
authors.affiliation: Department of Pharmacy Practice, Southwestern Oklahoma State University, Weatherford.
authors.forename: D F
authors.initials: DF
authors.lastname: Thompson
authors.forename: J R
authors.initials: JR
authors.lastname: Carter
mesh_terms: D000970:Antineoplastic Agents / Q000009:adverse effects*; D014150:Antipsychotic Agents / Q000009:adverse effects; D002121:Calcium Channel Blockers / Q000009:adverse effects*; D002188:Cannabis / Q000378:metabolism; D006177:Gynecomastia / Q000139:chemically induced*; D006635:Histamine H2 Antagonists / Q000009:adverse effects*; D006801:Humans; D007654:Ketoconazole / Q000009:adverse effects; D008297:Male; D013148:Spironolactone / Q000009:adverse effects
chemical_list: D000970:Antineoplastic Agents; D014150:Antipsychotic Agents; D002121:Calcium Channel Blockers; D006635:Histamine H2 Antagonists; D013148:Spironolactone; D007654:Ketoconazole